$DSCI News

Last published 9y ago

9y agoDSCIDerma Sciences Buys MEDIHONEY® Brand From Long-Term PartnerBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today announced that it has purchased the MEDIHONEY® brand and related intellectual property and goodwill from its long-term partner, New Zealand-based Comvita Limited. Consideration is an upfront payment of $13.25 million in cash, with an additional $5.0 mil ...
9y agoDSCI IARTDerma Sciences to Be Acquired by Integra LifeSciences for $7.00 Per Share of Common Stock in CashBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, today announced that it has signed a definitive agreement whereby Derma Sciences will be acquired by Integra LifeSciences Holdings Corporation (Nasdaq: IART) for $7.00 per share of common stock in cash, or a total of approximately $204 million, and $32.00 pe ...
10y agoDSCIDerma Sciences to Present at the Canaccord Genuity Medical Technologies & Diagnostics ForumBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that Stephen T. Wills, the Company’s Executive Chairman and Interim Principal Executive Officer, will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 17th at 10:30 a.m. Eastern time. The confere ...
10y agoDSCIDerma Sciences' (DSCI) CEO Stephen Wills on Q3 2016 Results - Earnings Call TranscriptEarnings Call Transcripts
10y agoDSCIDerma Sciences Reports 2016 Third Quarter Financial ResultsBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today reported financial and operating results for the three and nine months ended September 30, 2016.
10y agoDSCIDerma Sciences to Hold Third Quarter Financial Results Conference Call on November 10thBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that it will hold a conference call on November 10, 2016 to discuss the financial results for the third quarter of 2016. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
10y agoDSCIDerma Sciences to Present at the Ladenburg Thalmann 2016 Healthcare ConferenceBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that Stephen T. Wills, the Company’s Executive Chairman and Interim Principal Executive Officer, will present at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27th at 8:30 a.m. Eastern time. The program includes a for ...
10y agoDSCIDerma Sciences Completes the Sale of Its First Aid Products DivisionBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces the completion of the sale of its First Aid Division (FAD) to Dukal Corporation for $12.4 million, including inventory. The proposed sale was first announced on July 27, 2016.
10y agoDSCIDerma Sciences Receives Reimbursement Coding for New MEDIHONEY® Hydrogel DressingsBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announces the launch of new, MEDIHONEY® Hydrogel Sheet Dressings and the receipt of Healthcare Common Procedural Coding System (HCPCS) codes awarded on August 19, 2016 by the Centers for Medicare and Medicaid Services (CMS).
10y agoDSCIDerma Sciences’ AMNIOEXCEL® Now Eligible for Reimbursement by Medicare Administrative Contractor NGSBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces that National Government Services (NGS), a Medicare Administrative Contractor (MAC) for Part B serving States primarily in the Northeast and Midwest, and National MAC for Jurisdiction 6, has retired its local coverage determination (LCD) for cellula ...
10y agoDSCIDerma Sciences Names Russell Olsen President of Advanced Wound CareBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces the appointment of Russell Olsen as President of Advanced Wound Care. Mr. Olsen is President and Chief Executive Officer of BioD, LLC, a regenerative medicine products company Derma Sciences acquired earlier this month.
10y agoDSCIDerma Sciences Reports 2016 Second Quarter Financial ResultsBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today reported financial and operating results for the three and six months ended June 30, 2016.
10y agoDSCIDerma Sciences to Hold Second Quarter Financial Results Conference Call on August 9thBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that it will hold a conference call on August 9, 2016 to discuss the financial results for the second quarter of 2016. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
10y agoDSCIDerma Sciences to Acquire BioD, Solidify Its Leadership Position in Advanced Wound Care and Regenerative ProductsBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces the signing of a definitive agreement to acquire BioD, LLC for an immediate transaction value of $21.3 million and a potential total transaction value of an estimated $77.8 million. This includes an upfront payment of cash and common stock of $21.3 ...
10y agoDSCIDerma Sciences to Sell First Aid Products Division for Approximately $12.2 MillionBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces the signing of a definitive agreement to sell its First Aid Division (FAD) to Dukal Corporation for approximately $12.2 million, including inventory. Dukal is a privately-held supplier of a broad range of best-in-class disposable medical products an ...
10y agoDSCIDerma Sciences' (DSCI) CEO Steve Wills on Q1 2016 Results - Earnings Call TranscriptEarnings Call Transcripts
10y agoDSCIDerma Sciences Reports 2016 First Quarter Financial ResultsBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today reported financial and operating results for the three months ended March 31, 2016.
10y agoDSCIDerma Sciences to Hold First Quarter Financial Results Conference Call on May 11thBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that it will hold a conference call on May 11, 2016 to discuss the financial results for the first quarter of 2016. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
10y agoDSCIDerma Sciences Announces AMNIOEXCEL® Is Now Eligible for Reimbursement by Medicare Administrative Contractor CGSBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announces that CGS Administrators, LLC (CGS), a Medicare Administrative Contractor (MAC) for Parts A and B serving Kentucky and Ohio, has updated its local coverage determination (LCD) for cellular or tissue-based products (CTPs) of the lower extremity. As a ...
10y agoDSCIDerma Sciences' (DSCI) Management on Q4 2015 Results - Earnings Call TranscriptEarnings Call Transcripts
10y agoDSCIDerma Sciences Reports 2015 Fourth Quarter and Full Year Financial ResultsBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today reported financial and operating results for the three and 12 months ended December 31, 2015.
10y agoDSCIDerma Sciences to Hold Fourth Quarter Financial Results Conference Call on March 16thBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that it will hold a conference call on Wednesday, March 16, 2016 to discuss the financial results for the fourth quarter of 2015. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
10y agoDSCIFindings from Multicenter Study Comparing Derma Sciences’ AMNIOEXCEL® Against Standard-of-Care for Treating Diabetic Foot Ulcers Published in WOUNDS, a Leading Peer-Reviewed JournalBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces that a peer-reviewed comparative clinical study of AMNIOEXCEL® Amniotic Allograft Membrane plus standard-of-care (SOC), compared with SOC alone, for the closure of hard-to-treat diabetic foot ulcers, has been published. The results are statistically ...
10y agoDSCIDerma Sciences’ AMNIOEXCEL® Now Eligible for Reimbursement by Medicare Administrative Contractor WPSBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces that WPS Government Health Administrators (WPS), a Medicare Administrative Contractor (MAC) for Part B serving States primarily in the Midwest and National MAC for Jurisdiction 5, has retired its local coverage determination (LCD) for cellular or ti ...
10y agoDSCIDerma Sciences Provides 2015 Preliminary Net Sales and Introduces 2016 Financial GuidanceBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, provides preliminary net sales for the year ended December 31, 2015, announces various actions to reduce operating expenses and introduces financial guidance for the year ending December 31, 2016.
10y agoDSCI PTNDerma Sciences Announces Leadership and CEO TransitionBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (NASDAQ:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces that Stephen T. Wills, the Lead Director and a member of the Derma Sciences Board of Directors since 2000, has been unanimously appointed by the Board to serve as Interim Executive Chairman and Principal Executive Officer. The appointment of Mr. Wil ...
10y agoDSCIDerma Sciences to Participate in the 27th Annual Piper Jaffray Healthcare ConferenceBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that Edward J. Quilty, the Company’s chairman and chief executive officer, will participate in a “Fireside Chat” at the 27th Annual Piper Jaffray Healthcare Conference on Wednesday, December 2, 2015 at 9:00 a.m. Eastern time. The conference i ...
10y agoDSCIDerma Sciences to Participate in the Canaccord Genuity 2015 Medical Technology & Diagnostics ForumBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that Edward J. Quilty, the Company’s chairman and chief executive officer, will participate in a “Fireside Chat” at the Canaccord Genuity 2015 Medical Technology & Diagnostics Forum on Thursday, November 19, 2015 at 3:00 p.m. Eastern time. The ...
11y agoDSCIDerma Sciences Announces Results of Futility Analyses for Phase 3 Clinical Trials of Aclerastide in Diabetic Foot Ulcer HealingBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announces the termination of its Phase 3 clinical trials with aclerastide (DSC127) for diabetic foot ulcer healing. This action is based on futility determinations conducted by the Data Monitoring Committee (DMC) for the planned, pre-specified interim analys ...
11y agoDSCIDerma Sciences to Hold Conference Call on November 12 to Discuss Data Monitoring Committee Pre-Specified Interim Analysis of the Aclerastide Phase 3 TrialsBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, will issue a news release at 7:30 a.m. Eastern time on November 12 announcing the findings of the Data Monitoring Committee planned, pre-specified interim analysis of the aclerastide Phase 3 clinical trials for the closure of diabetic foot ulcers. A conferenc ...
11y agoDSCIDerma Sciences Reports Third Quarter 2015 Financial ResultsBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today reported financial and operating results for the three and nine months ended September 30, 2015.
11y agoDSCIDerma Sciences to Hold Third Quarter Financial Results Conference Call on November 9thBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that it will hold a conference call on Monday, November 9, 2015 to discuss the financial results for the third quarter of 2015. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
11y agoDSCICORRECTING and REPLACING Derma Sciences Reports Second Quarter Financial ResultsBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--In the Management Commentary section, fifth graph, last sentence should read: We continue to expect full-year sales of $43.8 million for the TWC business in 2015,” added Mr. Quilty (instead of $44.3 million).
11y agoDSCIDerma Sciences to Present at the Canaccord Genuity Global Growth ConferenceBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that Edward J. Quilty, the Company’s chairman and chief executive officer, will present a corporate overview and update at the Canaccord Genuity Global Growth Conference on August 13, 2015 at 2:00 p.m. Eastern time. The conference is being hel ...
11y agoDSCIDerma Sciences to Hold Second Quarter Financial Results Conference Call on August 10thBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound care, announced today that it will hold a conference call on August 10, 2015 to discuss the financial results for the second quarter of 2015. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
11y agoDSCIDerma Sciences Announces Publication in Advances in Wound CareBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announces the publication of a review of the current clinical development program for aclerastide (DSC127), a patented peptide analog of angiotensin, as a potential treatment for the closure of diabetic foot ulcers (DFUs) in an article titled, “NorLeu3-Angio ...
11y agoDSCIDerma Sciences Completes Non-Clinical Aclerastide Toxicology ProgramBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces that the required two-year animal carcinogenicity study for aclerastide has produced “clean results” related to safety findings and, in particular, carcinogenicity. This was the final study agreed to with the FDA for toxicological assessment.
11y agoDSCIDerma Sciences Announces Medicare Coverage Reinstated For MEDIHONEY® Products with Reimbursable Codes by Centers for Medicare & Medicaid ServicesBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces that the Centers for Medicare & Medicaid Services (CMS) has reinstated coverage and assigned a reimbursable code for MEDIHONEY® dressings effective immediately.
11y agoDSCIDerma Sciences Provides Update on Aclerastide Phase 3 TrialsBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, reports the halfway point of enrollment in the Phase 3 program with aclerastide (DSC127) in subjects with diabetic foot ulcers. The clinical trial sites contributing at this time are from the U.S. (including Puerto Rico), Canada and South Africa. The Company ...
11y agoDSCIDerma Sciences Reports First Quarter 2015 Financial ResultsBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today reported financial and operating results for the three months ended March 31, 2015.
11y agoDSCIDerma Sciences to Hold First Quarter Financial Results Conference Call on May 11ThBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound care, announced today that it will hold a conference call on May 11, 2015 to discuss the financial results for the first quarter of 2015. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
11y agoDSCIDerma Sciences Reports Fourth Quarter and Year Ended Financial ResultsBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today reported financial and operating results for the three months and year ended December 31, 2014.
11y agoDSCIDerma Sciences Names Pharmaceutical Development Leader John Caminis, M.D. as Chief Medical OfficerBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announces the appointment of John Caminis, M.D. to the newly created position of chief medical officer. Dr. Caminis is a seasoned pharmaceutical physician with particular expertise in clinical drug development, and will report to Edward J. Quilty, the company ...
11y agoDSCIDerma Sciences to Hold Fourth Quarter Financial Results Conference Call on March 12thBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that it will hold a conference call on Thursday, March 12, 2015 to discuss its financial results for the fourth quarter and full year 2014. In addition, management will provide a business update and a discussion on recent and upcoming mileston ...
11y agoDSCIDerma Sciences to Present at the 27th Annual Roth ConferenceBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that Edward J. Quilty, the Company’s chairman and chief executive officer, will present a corporate overview and update at the 27th Annual ROTH Conference on March 10, 2015 at 1:30 p.m. Pacific time. The conference is being held at the Ritz Ca ...
11y agoDSCIDerma Sciences Introduces 2015 Financial Guidance and Provides 2014 Preliminary Net SalesBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, introduces financial guidance for the year ended December 31, 2015 and provides preliminary net sales for the year ended December 31, 2014.
11y agoDSCIDerma Sciences To Participate in Two Upcoming Investor Conferences in DecemberBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, today announced that management will be participating in two upcoming investor conferences.
12y agoDSCIDerma Sciences to Participate in Canaccord Genuity Medical Technologies and Diagnostics ForumBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today announced that Edward J. Quilty, the Company’s chairman and chief executive officer will participate in a “Fireside Chat” at the Canaccord Genuity Medical Technology & Diagnostics Forum on Thursday, November 20th at 8:30 a.m. ET. The conference will be ...
12y agoDSCIDerma Sciences Reports Third Quarter Financial ResultsBusiness WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today reported financial and operating results for the three and nine months ended September 30, 2014.
12y agoDSCINewly Published Final CMS Payments for 2015 Favorably Impact Derma Sciences’ TCC-EZ® and AMNIOEXCEL®Business WirePRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq:DSCI), a tissue regeneration company focused on advanced wound and burn care, today announced that on October 31, 2014 the Centers for Medicare and Medicaid Services (CMS) issued the final rule for hospital outpatient prospective payment to take effect January 1, 2015. Included in the final rule are payment amounts associated with the ...